Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Clindamycin is a semi-synthetic lincosamide antibiotic used to treat a variety of serious infections caused by susceptible microorganisms, including anaerobic bacteria and certain gram-positive cocci such as staphylococci and streptococci. It is also used topically for acne vulgaris. Clindamycin works by inhibiting bacterial protein synthesis through binding to the 23S RNA of the 50S subunit of the bacterial ribosome, thereby impeding ribosomal assembly and translation processes. This action results in bacteriostatic effects but can be bactericidal depending on concentration and organism. Clindamycin was developed by chemically modifying lincomycin, which was originally isolated from Streptomyces lincolnensis. It is indicated for infections such as lower respiratory tract infections (including pneumonia), skin and soft tissue infections, bone and joint infections (including osteomyelitis), intra-abdominal infections (such as peritonitis), gynecological infections (such as endometritis), septicemia, and severe acne[1][2][3][5][8].
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on clindamycin.